(Q46151045)
Statements
Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan (English)
Frédéric Bibeau
Evelyne Lopez-Crapez
Frédéric Di Fiore
Simon Thezenas
France Blanchard
Aude Lamy
Frédérique Penault-Llorca
Thierry Frébourg
Pierre Michel
Jean-Christophe Sabourin
Florence Boissière-Michot
21 January 2009